Pharmaceutical

Rhythm expands obesity portfolio with Phase II weight loss drug for $100m

Rhythm to acquire global rights for South Korean LG Chem’s oral obesity drug LB54640 for $100m in cash and equity.

Jan 5, 2024 - 18:00
Rhythm expands obesity portfolio with Phase II weight loss drug for $100m
Rhythm to acquire global rights for South Korean LG Chem’s oral obesity drug LB54640 for $100m in cash and equity.
Read the original article

Tags:

Previous Article

Pharmaceutical Technology Excellence Awards 2023: KAI Conversations

Next Article

Boehringer and 3T Biosciences partner to develop cancer immunotherapies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: After late start, Eli Lilly has the momentum in battle for $30 billion weight loss market

STAT+: After late start, Eli Lilly has the momentum in ...

Jun 28, 2023

STAT+: Pharmalittle: FDA panel to review over-the-counter birth control pill; Alzheimer’s drugs may lead to haves and have-nots

STAT+: Pharmalittle: FDA panel to review over-the-count...

May 9, 2023

6 burning questions about how the FDA will handle conflicting abortion pill decisions

6 burning questions about how the FDA will handle confl...

Apr 11, 2023